The development and cross-validation of methods based on radioimmunoassay and LC/MS-MS for the quantification of the Class III antiarrhythmic agent, MK-0499, in human plasma and urine
- 1 July 1995
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 13 (8) , 937-950
- https://doi.org/10.1016/0731-7085(95)01540-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Fitting a straight line when both variables are subject to error: Pharmaceutical applicationsJournal of Pharmaceutical and Biomedical Analysis, 1994
- Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassayJournal of Pharmaceutical and Biomedical Analysis, 1994
- Determination of L-691,121, a new Class III antiarrhythmic, and its principal metabolite in plasma by differential radioimmunoassayJournal of Pharmaceutical and Biomedical Analysis, 1994
- Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: Implications in the treatment of restenosis after angioplastyJournal of the American College of Cardiology, 1994
- Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassayJournal of Pharmaceutical and Biomedical Analysis, 1993
- Delayed Ventricular Repolarization as an Anti-Arrhythmic PrincipleEuropean Heart Journal, 1985
- A Classification of Antiarrhythmic Actions Reassessed After a Decade of New DrugsThe Journal of Clinical Pharmacology, 1984
- PATHOLOGY OF SUDDEN CORONARY DEATH*Annals of the New York Academy of Sciences, 1982
- Two techniques for evaluating small molecule-macromolecule binding in complex systemAnalytical Biochemistry, 1975
- THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONSAnnals of the New York Academy of Sciences, 1949